Core Viewpoint - The company emphasizes that technological self-reliance is driving the industry towards domestic production, which further expands its development space and enhances market competitiveness across its four major industries [1] Market Position and Performance - The company's market share in the low-temperature storage industry continues to increase, with a projected market share of over 50% in plasma collection solutions by mid-2025, based on public and third-party bidding data [1] - The company ranks among the top three in the automated medication market and continues to break through in the domestic market for scientific instruments, with its total organic carbon analyzers and UV spectrophotometers being the top two domestic brands [1] - The centrifuge series has entered the top ten in market share among industry brands, while the biological safety cabinet has risen to the number one position nationwide, and the cultivation series maintains the highest market share among domestic brands [1] International Market Presence - Preliminary market research indicates that the company's three major low-temperature product lines hold the leading market share in 25 overseas countries [1]

Group 1 - JD Health held the 2026 Medical Device Development Strategy Conference, focusing on supply, AI, and medical services as core drivers for growth [1] - The company signed agreements with the top 100 global brands to launch new products in 2026, committing over 100 million in marketing resources [1] - JD Health aims to enhance its medical device sector by leveraging its supply chain, AI technology, and internet medical services to create a comprehensive ecosystem [1] Group 2 - In 2025, JD Health plans to deepen global brand collaborations and introduce overseas supplies through large-scale procurement [2] - The company will focus on high-potential areas such as chronic disease management and home healthcare, aiming to transition from single product sales to comprehensive health management solutions [2] - JD Health is committed to driving innovation and sustainable development in the medical device industry by enhancing product offerings and AI technology [2]

该股主要指标及行业内排名如下： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。迈得医疗（688310）主营业务：医用耗材智能装备的研发、生产、销售和服务,有效整 合医疗器械产品工艺、自动化、软件等方面的技术,形成独特的产品与服务优势,为医用耗材生产企业提 供自动化成套设备和软件服务整体式解决方案。 证券之星消息，截至2026年1月9日收盘，迈得医疗(688310)报收于16.13元，上涨1.13%，换手率1.6%， 成交量2.66万手，成交额4252.79万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成 ...

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has shown mixed financial performance, with revenue growth but a decline in net profit for the first three quarters of 2025 [2] - As of January 9, 2026, Xinmai Medical's stock closed at 97.94 yuan, up 1.25%, with a turnover rate of 1.42% and a trading volume of 17,500 hands, resulting in a transaction amount of 171 million yuan [1] - In terms of capital flow on January 9, 2026, the main funds had a net outflow of 838,300 yuan, accounting for 0.49% of the total transaction amount, while retail investors had a net inflow of 2.57 million yuan, accounting for 1.51% of the total transaction amount [1] Group 2 - Xinmai Medical's financial results for the first three quarters of 2025 show a main revenue of 1.015 billion yuan, a year-on-year increase of 4.66%, and a net profit attributable to shareholders of 429 million yuan, a year-on-year decrease of 22.46% [2] - The company's gross profit margin stands at 70.4%, with a debt ratio of 15.85% and investment income of 11.6 million yuan [2] - In the last 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 136.03 yuan [2]

证券日报网讯1月9日，海尔生物在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东总 数为13105户。 ...

（文章来源：证券日报） 证券日报网讯 1月9日，正海生物发布公告称，公司于近日取得由国家药品监督管理局下发的《中华人 民共和国医疗器械注册证》，产品名称为钙硅生物陶瓷口腔骨修复材料。 ...

（文章来源：证券日报） 证券日报网讯 1月9日，迈瑞医疗在互动平台回答投资者提问时表示，公司高度重视中小投资者的利益 保护。公司将通过如下措施加强投资者利益保护：1、以业绩增长筑牢利益根基：聚焦主业，通过持续 研发投入推动技术突破，深化境内外业务布局，释放增长潜力，以高质量经营提升公司内在价值，为中 小股东利益提供根本保障。2、以稳定分红实现股东回报：公司高度重视投资者回报，在兼顾全体股东 共同利益和公司长远发展的基础上，实施可持续的利润分配政策。公司已经编制、并经股东会审议通过 了《未来三年（2025—2027年）股东回报规划》，在具备利润分配条件的前提下，公司原则上每年度至 少进行一次利润分配，公司每年以现金方式分配的利润不少于当年实现的可供分配利润的65%。自公司 2018年上市以来，公司未进行过再融资，并连续七年实施分红，累计分红总额已达到373亿元（包含回 购股份20亿元），6倍于IPO募资额59.34亿元。未来，公司将继续兼顾战略发展规划和股东回报，在保 障公司内外部业务拓展的前提下，持续加大对股东的回报力度，以此为股东创造更大的价值。3、透 明、及时的信息披露机制：公司注重信息披露的重要性、针对 ...

本文字数：1471，阅读时长大约3分钟 2026.01.09 当前市场的上行趋势是否能够得以延续，后续增量资金来自何处？ 严凯文观察到，部分热门赛道交易拥挤度上升，或带来回调压力。不过，他认为，从中长期视角看，在 宏观政策托底、流动性环境友好的背景下，市场整体仍将保持震荡上行节奏。 作者 |第一财经 周楠 A股的"开门红"行情再上一个台阶。1月9日，沪指盘中突破4100点，创十年新高，两市成交额时隔近四 个月突破3万亿元。 截至9日收盘，上证指数报收4120.43点，涨0.92%；深成指和创业板指分别报收14120.15点和3327.81 点，涨幅1.15%和0.77%。两市成交额达到3.12万亿元，较前一交易日放量3224亿元。 当天盘面上，市场热点快速轮动，全市场超3900只个股上涨，AI应用概念集体爆发，易点天下20CM涨 停，利欧股份、浙文互联等涨停。同时，商业航天、可控核聚变等概念延续强势；下跌方面，脑机接口 概念下挫，美好医疗、倍益康跌超10%。 2026年开年至今，沪指已连续5个交易日（1月5日至9日）收于4000点上方，其中4个交易日收涨，仅在1 月8日微跌0.07%。 "市场在快速上行过程中 ...

每经AI快讯，康拓医疗（688314.SH）1月9日在投资者互动平台表示，公司美国控股子公司BIOPLATE 主营神经外科颅骨修补固定产品，包括钛材料修补固定产品、PEEK材料骨板、可吸收骨塞等。 （文章来源：每日经济新闻） ...

近日，由国家药监局器审中心牵头，山东省药监局主办的"春雨行动—医疗器械临床研究成果转化推进会"在济南召开。滕州市中心人 民医院器械科报送的"高流量吸氧雾化设备"项目成功入选山东省"春雨行动"重点项目，该项目也是全省唯一一个由县级医院独立申报 并入选的重点项目，标志着该院在医疗器械临床创新与成果转化领域取得重要突破。 | 51 | 多目标智能自适应脑机接口康 | 威海市立医院 | | --- | --- | --- | | | 复系统 | | | 52 | 微创脊柱外科远程手术机器人 | 山东大学 | | રે રે | 腰椎失稳智能辅助诊断软件 | 山东大学第二医院 | | ર્સ | 骨科医学影像智能测量软件 | 山东大学第二医院 | | રે રે | 三维正脊数字化系统 | 山东第一医科大学(山东省医学科学 | | | | 院) | | 56 | 上消化道早期肿瘤内镜影像辅 | 青岛美迪康数字工程有限公司 | | | 助诊断软件 | | | 57 | 腔内伤口测量系统 | 青岛市市立医院 | | રે 8 | 多模态影像智能诊断平台 | 威海市妇幼保健院 | | રે તે | AI 全自动光谱式高通量 ...